Kinetics of glycosaminoglycan deposition in splenic AA amyloidosis induced in mink

Scandinavian Journal of Immunology

Volumn 60, Issue 6, 2004, Pages 600-608

  Wien, Tale Norbye ^a   Sorby R ^b   Omtvedt, L A ^a   Landsverk, T ^b   Husby, G ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AGRIN; AMYLOID A PROTEIN; CHONDROITIN SULFATE; CONGO RED; DECORIN; DERMATAN SULFATE; EPITOPE; PERLECAN; PROTEOHEPARAN SULFATE;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MINK; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; SPLEEN;

AMYLOIDOSIS; ANIMALS; CHROMATOGRAPHY, ION EXCHANGE; GLYCOSAMINOGLYCANS; IMMUNOHISTOCHEMISTRY; KINETICS; MINK; SPLEEN;

EID: 10844249348     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01520.x     Document Type: Article

References (48)

1. Westermark P, Benson MD, Buxbaum JN et al. Amyloid fibril protein nomenclature 2002. Amyloid 2002;9:197-200.
2. Ancsin JB. Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid 2003;10:67-79.
3. Ailles L, Kisilevsky R, Young ID. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis. Lab Invest 1993;69:443-8.
4. Stenstad T, Magnus JH, Husby G. Characterization of proteoglycans associated with mouse splenic AA amyloidosis. Biochem J 1994;303: 663-70.
5. McCubbin WD, Kay CM, Narindrasorasak S, Kisilevsky R. Circular-dichroism studies on two murine serum amyloid A proteins. Biochem J 1988;256:775-83.
6. Castillo GM, Ngo C, Cummings J, Wight TN, Snow AD. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J Neurochem 1997;69:2452-65.
7. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995;1:143-8.
8. Zhu H, Yu J, Kindy MS. Inhibition of amyloidosis using low-molecular-weight heparins. Mol Med 2001;7:517-22.
9. Kisilevsky R, Szarek WA, Ancsin JB et al. Inhibition of amyloid A amyloidogenesis in vivo and in tissue culture by 4-deoxy analogues of peracetylated 2-acetamido-2-deoxy-alpha- and beta-d-glucose: implications for the treatment of various amyloidoses. Am J Pathol 2004;164:2127-37.
10. Kjellen L, Lindahl U. Proteoglycans: structures and interactions [published erratum appears in Annu Rev Biochem 1992;61:following viii]. Annu Rev Biochem 1991;60:443-75.
11. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998;67:609-52.
12. Saadi S, Wrenshall LE, Platt JL. Regional manifestations and control of the immune system. FASEB J 2002;16:849-56.
13. Husebekk A, Skogen B, Husby G, Marhaug G. Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol 1985;21:283-7.
14. Röcken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002;440:111-22.
15. Nordstoga K. Amyloidosis in mink induced by repeated injections of endotoxin. Acta Pathol Microbiol Scand [A] 1972;80:159-68.
16. Husby G, Natvig JB, Sletten K, Nordstoga K, Anders RF. An experimental model in mink for studying the relation between amyloid fibril protein AA and the related serum protein SAA. Scand J Immunol 1975;4:811-6.
17. Wien TN, Omtvedt LA, Landsverk T, Husby G. Characterization of proteoglycans and glycosaminoglycans in splenic AA amyloid induced in mink. Scand J Immunol 2000;52:576-83.
18. Wien TN, Sørby R, Espenes A et al. Splenic ellipsoids: an early target for deposition of AA amyloid induced in mink. Amyloid 2003;10:240-9.
19. Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem 1962;10:355-64.
20. Linke RP. Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence. Virchows Arch 2000;436: 439-48.
21. Bancroft JD. Enzyme histochemistry and its diagnostic applications. In: Bancroft JD, Gamble M, eds. Theory and Practise of Histological Techniques. London: Churchill Livingstone 2002, 593-620.
22. Horiguchi Y, Couchman JR, Ljubimov AV, Yamasaki H, Fine JD. Distribution, ultrastructural localization, and ontogeny of the core protein of a heparan sulfate proteoglycan in human skin and other basement membranes. J Histochem Cytochem 1989;37: 961-70.
23. Brennan MJ, Oldberg A, Hayman EG, Ruoslahti E. Effect of a proteoglycan produced by rat tumor cells on their adhesion to fibronectin-collagen substrata. Cancer Res 1983;43:4302-7.
24. Kure S, Yoshie O. A syngeneic monoclonal antibody to murine Meth-A sarcoma (HepSS-1) recognizes heparan sulfate glycosaminoglycan (HS-GAG): cell density and transformation dependent alteration in cell surface HS-GAG defined by HepSS-1. J Immunol 1986;137:3900-8.
25. Raats CJ, Bakker MA, Hoch W et al. Differential expression of agrin in renal basement membranes as revealed by domain-specific antibodies. J Biol Chem 1998;273:17832-8.
26. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethyl-methylene blue. Biochim Biophys Acta 1986;883:173-7.
27. Heinegard D, Sommarin Y. Isolation and characterization of proteoglycans. Methods Enzymol 1987;144:319-72.
28. Shively JE, Conrad HE. Formation of anhydrosugars in the chemical depolymerization of heparin. Biochemistry 1976;15:3932-42.
29. Saito H, Yamagata T, Suzuki S. Enzymatic methods for the determination of small quantities of isomeric chondroitin sulfates. J Biol Chem 1968;243:1536-42.
30. Magnus JH, Stenstad T. Proteoglycans and the extracellular matrix in amyloidosis. Amyloid 1997;4:121-34.
31. Moss J, Shore I, Woodrow D. An ultrastructural study of the colocalization of biglycan and decorin with AA amyloid fibrils in human renal glomeruli. Amyloid 1998;5:43-8.
32. Stokes MB, Holler S, Cui Y et al. Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney Int 2000;57:487-98.
33. Snow AD, Mar H, Nochlin D, Kresse H, Wight TN. Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease. J Histochem Cytochem 1992;40:105-13.
34. Comalada M, Cardo M, Xaus J et al. Decorin reverses the repressive effect of autocrine-produced TGF-beta on mouse macrophage activation. J Immunol 2003;170:4450-6.
35. Egeberg M, Kjeken R, Kolset SO, Berg T, Prydz K. Internalization and stepwise degradation of heparan sulfate proteoglycans in rat hepatocytes. Biochim Biophys Acta 2001;1541:135-49.
36. van den Born J, van den Heuvel LP, Bakker MA et al. Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 1993;43:454-63.
37. Verbeek MM, Otte-Höller I, van den Born J et al. Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. Am J Pathol 1999;155:2115-25.
38. Cotman SL, Halfter W, Cole GJ. Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain. Mol Cell Neurosci 2000;15:183-98.
39. Khan AA, Bose C, Yam LS, Soloski MJ, Rupp F. Physiological regulation of the immunological synapse by agrin. Science 2001; 292:1681-6.
40. Bezakova G, Lømo T. Muscle activity and muscle agrin regulate the organization of cytoskeletal proteins and attached acetylcholine receptor (AchR) aggregates in skeletal muscle fibets. J Cell Biol 2001;153:1453-63.
41. van den Born J, van den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, Berden JH. Monoclonal antibodies against the protein core and glycosaminoglycan side chain of glomerular basement membrane heparan sulfate proteoglycan: characterization and immunohistological application in human tissues. J Histochem Cytochem 1994;42:89-102.
42. Wong S, Kisilevsky R. Influence of sulphate ions on the structure of AA amyloid fibrils. Scand J Immunol 1990;32:225-32.
43. Fraser PE, Nguyen JT, Chin DT, Kirschner DA. Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J Neurochem 1992;59: 1531-40.
44. Castillo GM, Cummings JA, Yang W et al. Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes 1998;47:612-20.
45. Linker A, Carney HC. Presence and role of glycosaminoglycans in amyloidosis. Lab Invest 1987;57:297-305.
46. Snow AD, Kisilevsky R, Stephens C, Anastassiades T. Characterization of tissue and plasma glycosaminoglycans during experimental AA amyloidosis and acute inflammation. Qualitative and quantitative analysis. Lab Invest 1987;56:665-75.
47. Eikelenboom P. Dendritic cells in the rat spleen follicles. A combined immuno- and enzyme histochemical study. Cell Tissue Res 1978;190:79-87.
48. Takahashi M, Yokota T, Kawano H, Gondo T, Ishihara T, Uchino F. Ultrastructural evidence for intracellular formation of amyloid fibrils in macrophages. Virchows Arch A Pathol Anat Hisropathol 1989;415:411-9.